Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation

(P145) ANTHOCYANIN AND PECTIN COMPLEXES ATTENUATE ULCERATIVE COLITIS IN IL-10 KNOCKOUT MICE

(P146) CANNABINOID MEDICINAL CHEMISTRY HAS VAST IMPACT ON PHARMACOLOGY IN MOUSE AND RAT MODELS OF INFLAMMATORY BOWEL DISEASE (IBD)

(P147) DIETARY INTAKE OF ODD-CHAIN FATTY ACID REDUCES INFLAMMATION AND ENHANCES GUT INTEGRITY IN IBD MOUSE MODEL

(P148) FIRST-IN-CLASS CLINICAL STAGE DEOXYCYTIDINE KINASE INHIBITOR TRE-515 BLOCKS INFLAMMATORY BOWEL DISEASE SYMPTOMS IN AN ADOPTIVE CD4 T CELL TRANSFER MOUSE MODEL

(P149) GLATIRAMER ACETATE (GA) LONG-ACTING INJECTION (GA DEPOT) EFFECT IN A MOUSE MODEL OF IBD

(P150) IMMUNE MODULATION BY MACROPHAGE GALACTOSE C-TYPE LECTIN ALLEVIATE MURINE MODEL OF COLITIS

(P151) LYTIC PHAGE ATTENUATES COLITIS SEVERITY IN GNOTOBIOTIC MICE COLONIZED WITH IBD-ASSOCIATED E. COLI NRG857C

(P152) ORAL DELIVERY OF BUDESONIDE-LOADED NANOPARTICLES WITH OXIDATIVE-RESPONSIVE DEPEGYLATION ENHANCES INFLAMMATION RESOLUTION IN COLITIS-INDUCED MICE

(P153) PALI-2108, A COLON SPECIFC PDE4B INHIBITOR PRODRUG IS ACTIVATED IN THE COLON AND REDUCES ULCERATIVE COLITIS SYMPTOMS IN AN ACUTE COLITIS DSS MOUSE MODEL

(P154) TARGETING MYD88-JAK2 SIGNALING IN ABERRANTLY DIFFERENTIATED MESENCHYMAL PROGENITORS IN ULCERATIVE COLITIS

(P155) TOWARDS DEVELOPMENT OF TARGETED THERAPEUTICS FOR CHRONIC PAIN IN IBD: ANALGESIC EFFICACY OF AN ORAL GCPII INHIBITOR IN PRECLINICAL VISCERAL PAIN MODELS